Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL
文献类型：期刊论文
| 作者 | Liu, X; Cao, X; Wei, R; Cai, Y; Li, H; Gui, J; Zhong, D; Liu, XY; Huang, K |
| 刊名 | CANCER GENE THERAPY
 |
| 出版日期 | 2012 |
| 卷号 | 19期号:1页码:49-57 |
| 关键词 | cancer-targeting gene-viro-therapy liver cancer interleukin-24 tumor necrosis factor-related apoptosis-inducing ligand apoptosis |
| 通讯作者 | Huang, K (reprint author), Huazhong Univ Sci & Technol, Tongji Sch Pharm, 13 Hang Kong Rd, Wuhan 430030, Hubei, Peoples R China.,xyliu@sibs.ac.cn ; kunhuang2008@hotmail.com |
| 英文摘要 | Cancer-targeting gene-viro-therapy is a promising cancer therapeutic strategy that strengthens the antitumor effect of oncolytic viruses by expressing an inserted foreign antitumor gene. To achieve liver cancer targeting and to improve the safety of the ZD55 vector (a widely-used E1B55KD gene-deleted oncolytic adenoviral vector (OV), we previously constructed), we designed a novel OV named Ad center dot AFP center dot D55 that selectively replicates in hepatocellular carcinoma (HCC) cells by replacing the E1A promoter with the liver-cancer specific a-Fetoprotein (AFP) promoter based on the ZD55 vector. We found that the oncolytic adenoviruses Ad center dot AFP center dot D55-IL-24 and Ad center dot AFP center dot D55-TRAIL express tumor-suppressor gene interleukin-24 (IL-24) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), respectively, significantly suppressed the HCC cell growth in vitro by inducing apoptosis by the caspase-8 and mitochondria-dependent caspase-9 signaling pathways. Furthermore, the combined treatment of Ad center dot AFP center dot D55-IL-24 and Ad center dot AFP center dot D55-TRAIL showed strong antitumor effects in vivo by significantly inhibiting the tumor growth in HCC HuH-7 cell xenograft mice, and markedly increasing animal survival rate. Therefore, this novel HCC cell-targeting OV carrying tumor-suppressor genes may provide a promising approach for liver cancer gene therapy. Cancer Gene Therapy (2012) 19, 49-57; doi: 10.1038/cgt.2011.67; published online 7 October 2011 |
| 学科主题 | Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Research & Experimental Medicine |
| 类目[WOS] | Biotechnology & Applied Microbiology ; Oncology ; Genetics & Heredity ; Medicine, Research & Experimental |
| 关键词[WOS] | ANTITUMOR-ACTIVITY ; HEPATOCELLULAR-CARCINOMA ; TUMOR ; APOPTOSIS ; VIROTHERAPY ; CELLS ; ADENOCARCINOMA ; ERADICATION ; EXPRESSION ; HEPATOMA |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000298233200005 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/536]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Liu, X,Cao, X,Wei, R,et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL[J]. CANCER GENE THERAPY,2012,19(1):49-57. |
| APA | Liu, X.,Cao, X.,Wei, R.,Cai, Y.,Li, H.,...&Huang, K.(2012).Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.CANCER GENE THERAPY,19(1),49-57. |
| MLA | Liu, X,et al."Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL".CANCER GENE THERAPY 19.1(2012):49-57. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。